This market is expected to reach USD 739.9 Million by 2021 from USD 557.1 Million in 2016, growing at a CAGR of 5.8%. The global in situ hybridization market is segmented on the basis of technique, application, end user, and region.

The growth of the overall market can be attributed to the increasing diagnosis and growing incidence & prevalence of cancer, technology advancements in therapeutics, and increasing government initiatives globally.

By application, the in situ hybridization market is categorized into cancer diagnosis, cytology, neuroscience, immunology and infectious diseases. The cancer diagnosis segment is expected to command the largest share of the global in situ hybridization market, by application in 2016. This segment is also projected to grow at the highest CAGR during the forecast period (2016-2021). This is attributed to factors such as rising prevalence of cancer, increasing adoption of FISH in diagnosis of cancer, and rising demand for FISH-based companion diagnostics for cancer.

Download PDF Brochure@ 
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=212028829

On the basis of end users, the global in situ hybridization market is segmented into molecular diagnostic laboratories, academic & research institutes, contract research organizations, and pharmaceutical & biotechnology companies. In 2016, the molecular diagnostic laboratories segment is estimated to account for the largest share of the global in situ hybridization market, by end user. This segment is also projected to grow at the highest CAGR during the forecast period (2016-2021). This can be attributed to the availability of specialized skill sets in molecular diagnostic laboratories for ISH technique, rising prevalence of cancer coupled with genetic abnormalities, and increasing adoption of FISH in diagnosis of cancer and genetic abnormalities.

On the basis of region, the global market is divided into North America, Europe, Asia-Pacific, and the Rest of the World. In 2016, North America is poised to account for the largest share of the in situ hybridization market, followed by Europe and Asia-Pacific. However, the Asia-Pacific market is slated to grow at the highest CAGR during the forecast period.

Factors such as growing presence of international players in China and India, increasing cancer prevalence and diagnosis, and increased healthcare expenditure across the Asia-Pacific region are drivers for the in situ hybridization market in this region.

Increasing diagnosis and growing incidence & prevalence of cancer, technology advancements in therapeutics, increasing government initiatives globally are some of the pivotal factors driving the growth of the global in situ hybridization market.

Abbott Laboratories, Inc. (U.S.), F. Hoffmann-La Roche AG (Switzerland), Leica Biosystems Nussloch GmbH (Germany), Agilent Technologies (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Merck KGaA (Germany), PerkinElmer, Inc. (U.S.), Exiqon A/S (Denmark), BioGenex Laboratories, Inc. (U.S.), Advanced Cell Diagnostics, Inc. (U.S.), and Bio SB Inc. (U.S.) are some of the key players in the in situ hybridization market worldwide.

Request Sample Pages@ 
https://www.marketsandmarkets.com/requestsampleNew.asp?id=212028829

The mergers & acquisitions and new product development by both the key players, Abbott (U.S.) and F. Hoffmann-La Roche Ltd. (Switzerland) will help boost the growth of the global in-situ hybridization market during forecast period.

This report provides a detailed analysis of the in-situ hybridization market and segments the same on the basis of type, application, end-user and geography. Based on type, the market has been segmented into DNA in-situ hybridization and RNA in-situ hybridization. Based on application, the market has been segmented into cancer diagnostics, immunology, neurosciences, cytology, and others. Based on end user, the market has been segmented into hospitals, pharma & biotech companies, research labs, and contract research organizations (CROs). Based on geography, the market has been segmented into regions, such as the North America, Europe, and Asia-Pacific.

About MarketsandMarkets™
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:
Mr. Shelly Singh
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
[email protected]